Claire Harrison, MD, FRCP, FRCPath, Guy's & St Thomas' NHS Foundation Trust, London, UK, discusses the relevance of JAK2- and CALR-targeted therapies for patients with myeloproliferative neoplasms (MPNs). Prof. Harrison explains that the discovery of the JAK2 mutation has led to the development of many effective therapy options for patients, and that studies with anti-CALR antibodies show promise for treating patients with this mutation. Prof. Harrison further highlights the value of other strategies, such as bispecific antibodies (BsAbs), CAR-T cells, vaccinations, and the JAK inhibitor ruxolitinib. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть